Vela Technologies PLC Update on investment in 3Legs Resources plc (5452E)
04 November 2015 - 1:18PM
UK Regulatory
TIDMVELA
RNS Number : 5452E
Vela Technologies PLC
04 November 2015
Vela Technologies plc
("Vela" or the "Company")
Update on investment in 3Legs Resources plc
Vela Technologies plc (AIM: VELA), the investing company focused
on early stage and pre-IPO disruptive technology investments, notes
the announcement released earlier today by 3Legs Resources plc
("3Legs").
As at the date of this announcement Vela holds 23,500,000 shares
in 3Legs which represents 3.80 per cent. of the existing voting
rights of 3Legs.
Vela's shareholding in 3Legs has been acquired at an average
price of 0.213 pence per share for a total consideration of
approximately GBP50,090.
3Legs is an Isle of Man incorporated investing company whose
shares are traded on AIM. The investing policy of 3Legs is to seek
to invest in and/or acquire companies within the life sciences and
related technologies sector. As announced today 3Legs has recently
signed non-binding heads of terms in connection with the proposed
acquisition by 3Legs of SalvaRx Limited ("SalvaRx"), a company in
which 3Legs owns an 11.1 per cent. shareholding. On 30 September,
3Legs reported that it had subscribed GBP215,000 for new shares in
SalvaRx in conjunction with a subscription for the same amount by
Jim Mellon and Greg Bailey, both directors and substantial
shareholders of 3Legs.
A copy of 3Legs's announcement is below and a link to the 3Legs
announcement can be found at:
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12567318.html
For further information please contact:
Vela Technologies plc
Brent Fitzpatrick, Non-Executive
Chairman Tel: +44 (0) 7802 262 443
Antony Laiker, Director
Allenby Capital Limited
(Nominated Adviser)
Nick Athanas/Katrina Perez/James Tel: +44 (0) 20 3328 5656
Reeve
Vicarage Capital Limited
(Broker) Tel: +44 (0) 20 3651 2910
Rupert Williams/Jeremy Woodgate
3Legs Resources plc
("3Legs" or the "Company")
Proposed Acquisition and Suspension of Trading
3Legs announces that, in accordance with Rule 15 of the AIM
Rules for Companies ("AIM Rules"), the Company's shares have been
suspended from trading on AIM from 7.30 a.m. today as a result of
the Company not having completed an acquisition which constitutes a
reverse takeover under the AIM Rules, or otherwise implemented its
investing policy within 12 months of becoming an investing company.
The Company is actively working to implement its investing policy
and the Board is pleased to provide the following update.
The Company has recently signed non-binding heads of terms in
connection with the proposed acquisition of SalvaRx Limited
("SalvaRx"), a company in which 3Legs owns an 11.1 per cent.
shareholding. On 30 September, the Company reported that it had
subscribed GBP215,000 for new shares in SalvaRx in conjunction with
a subscription for the same amount by Jim Mellon and Greg Bailey,
both directors and substantial shareholders of 3Legs.
SalvaRx owns 60.5% of iOx Therapeutics Limited ("iOx"), a new
company which is developing a series of compounds for cancer
immunotherapy. As previously announced, iOx's technology is based
on a discovery by Professor Vincenzo Cerundolo MD, PhD, the
Director of the Human Immunology Unit at the Weatherall Institute
of Molecular Medicine at Oxford University and supported by the
Ludwig Institute for Cancer Research. Its compounds stimulate
invariant natural killer T cells, and preclinical testing in
several cancer models suggest the compounds can inhibit the growth
of tumours.
The transaction, should it proceed, will be structured by way of
an acquisition of all the shares in SalvaRx not already owned by
Company with the consideration being satisfied by the issue of new
shares in the Company. Due to its size in relation to the Company,
the proposed acquisition of SalvaRx would constitute a "reverse
takeover" under the AIM Rules. Therefore the Company's shares will
remain suspended until such time as either an admission document
setting out details of the proposed acquisition is published or, in
the event that the transaction does not proceed, the Company has
taken other steps to implement its Investing Policy.
In the event that the Company is unable to implement its
investing policy within the next six months (i.e. by 4 May 2016),
admission of the Company's shares will be cancelled in accordance
with Rule 41 of the AIM Rules.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIBTTMBBMBJA
(END) Dow Jones Newswires
November 04, 2015 07:18 ET (12:18 GMT)
Asia Digital (LSE:ADH)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Asia Digital (LSE:ADH)
Historical Stock Chart
Von Jun 2023 bis Jun 2024